Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

NCT05402722 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: Eribulin
DRUG: anti-PD-1 antibody

Sponsor

Beijing 302 Hospital